loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Olverembatinib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Olverembatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    2D Structure
    1. Also known as: 1257628-77-5, Gzd824, Olverembatinib, Gzd-824, Hqp1351, Olverembatinib [usan]
    Molecular Formula
    C29H27F3N6O
    Molecular Weight
    532.6  g/mol
    InChI Key
    TZKBVRDEOITLRB-UHFFFAOYSA-N
    FDA UNII
    KV1M7Q3CBP
    Olverembatinib is an orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
    2.1.2 InChI
    InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
    2.1.3 InChI Key
    TZKBVRDEOITLRB-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4
    2.2 Other Identifiers
    2.2.1 UNII
    KV1M7Q3CBP
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-((1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

    2. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide

    3. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-, Methanesulfonate (1:2)

    4. D-824

    5. D-824 Dimesylate

    6. D824

    7. Gzd-824

    8. Gzd-824 Dimesylate

    9. Gzd824

    10. Hqp-1351

    11. Hqp-1351 Dimesylate

    12. Hqp1351

    13. Hqp1351 Dimesylate

    14. Olverembatinib

    15. Olverembatinib Dimesylate

    2.3.2 Depositor-Supplied Synonyms

    1. 1257628-77-5

    2. Gzd824

    3. Olverembatinib

    4. Gzd-824

    5. Hqp1351

    6. Olverembatinib [usan]

    7. Hqp-1351

    8. Kv1m7q3cbp

    9. 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide

    10. Chembl2316582

    11. D-824

    12. Gzd 824

    13. Benzamide, 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-

    14. Olverembatinib Dimesylate

    15. Hqp1351 Dimesylate

    16. Hqp-1351 Dimesylate

    17. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide

    18. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-

    19. 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide

    20. 4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1h-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide

    21. Hqp1351 Free Base

    22. Hqp-1351 Free Base

    23. Unii-kv1m7q3cbp

    24. Olverembatinib [inn]

    25. Schembl3424528

    26. Olverembatinib [who-dd]

    27. Gtpl10630

    28. Ex-a829

    29. Bcp07502

    30. Bdbm50425780

    31. Who 11221

    32. Zinc95594040

    33. Akos026750647

    34. Cs-1444

    35. Sb16617

    36. Compound 10a [pmid: 23301703]

    37. Ncgc00351607-06

    38. Ac-35436

    39. As-75170

    40. Hy-15666

    41. Ft-0700150

    42. A16264

    43. C72036

    44. A899056

    45. J-690110

    2.4 Create Date
    2011-04-25
    3 Chemical and Physical Properties
    Molecular Weight 532.6 g/mol
    Molecular Formula C29H27F3N6O
    XLogP34.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count6
    Exact Mass532.21984399 g/mol
    Monoisotopic Mass532.21984399 g/mol
    Topological Polar Surface Area77.2 Ų
    Heavy Atom Count39
    Formal Charge0
    Complexity910
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    Post Enquiry
    POST ENQUIRY